Phase ii prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 1093-1098

  Santoro, A ^a   Comandone, A ^b   Basso, U ^c   Soto Parra, H ^d   De Sanctis, R ^a   Stroppa, E ^e   Marcon, I ^f   Giordano, L ^a   Lutman, F R ^a   Boglione, A ^b   Bertuzzi, A ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b GRADENIGO HOSPITAL   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e GUGLIELMO DA SALICETO HOSPITAL   (Italy)

^f OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Angiosarcoma; Leiomyosarcoma; Soft tissue sarcoma; Sorafenib; Vascular sarcoma

Indexed keywords

ANTHRACYCLINE; SORAFENIB;

ADULT; ADVANCED CANCER; ADVERSE DRUG REACTION; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SKIN REACTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOPHOSPHATEMIA; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SKIN TOXICITY; SOFT TISSUE SARCOMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR TUMOR;

EID: 84875632694     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds607     Document Type: Article

References (29)

1. Brennan MF, Singer S, Maki R et al.. Soft tissue sarcoma. In DeVita VT, Heilman S, Rosenberg SA (eds), Cancer: Principles and Practice of Oncology, 8th edition. Philadelphia, PA: Lipincott Williams & Wilkins 2008; 1741-1794.
2. Bay JO, Ray-Coquard I, Fayette J et al.. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 2006; 119: 706-711.
3. Maki RG, Wathen JK, Patel SR et al.. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007; 25: 2755-2763.
4. Fletcher CDM, Unni KK, Mertens F. World Health Organization Classification of Tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002.
5. Pantanowitz L, Dezube BJ, Pinkus GS et al.. Histological characterization of regression in acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Cutan Pathol 2004; 31: 26-34.
6. Hogendoorn PC, Collin F, Daugaard S et al.. Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment. Eur J Cancer 2004; 40: 1644-1654.
7. Mahalingam D, Mita A, Sankhala K et al.. Targeting sarcomas: novel biological agents and future perspectives. Curr Drug Targets 2009; 10: 937-949.
8. Mocellin S, Rossi CR, Brandes A et al.. Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev 2006; 32: 9-27.
9. Demetri GD, van Oosterom AT, Garrett CR et al.. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338.
10. Agulnik M, Okuno SH, Von Mehren M et al.. An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma. J Clin Oncol 2009; 27 (15 Suppl). Abstract 10522.
11. Chawla SP, Staddon AP, Baker LH et al.. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012; 30(1): 78-84.
12. Mita M, Sankhala K, Mita A et al.. A phase II study of intravenous Reolysin (Wild Type Reovirus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. Abstract presented at the CTOS 14th Annual Meeting, 2008; 66: Abstract 35067.
13. Rudek MA, Figg WD, Dyer V et al.. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001; 19: 584-592.
14. Syed S, Takimoto C, Hidalgo M et al.. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res 2004; 10: 6512-6521.
15. Verschraegen CF, Arias-Pulido H, Lee SJ et al.. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann Oncol 2012; 23(3): 785-790.
16. Heinrich MC, Owzar K, Corless CL et al.. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26(33): 5360-7.
17. Verweij J, Casali PG, Zalcberg J et al.. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-1134.
18. Strumberg D, Richly H, Hilger RA et al.. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23(5): 965-72.
19. Adnane L, Trail PA, Taylor I et al.. Sorafenib (BAY 43-9006, Nexavar®), a dualaction inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006; 407: 597-612.
20. Wilhelm S, Carter C, Lynch M et al.. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-844.
21. Grignani G, Palmerini E, Dileo P et al.. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 2012; 23(2): 508-516.
22. Pacey S, Ratain MJ, Flaherty KT et al.. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs 2011; 29(3): 481-488.
23. Maki RG, D'Adamo DR, Keohan ML et al.. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27: 3133-3140.
24. Van Glabbeke M, Verweij J, Judson I et al.. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38: 543-549.
25. Verweij J. Soft tissue sarcoma trials; one size no longer fits all. J Clin Oncol 2009; 27(9): 3085-3087.
26. Basso U, Brunello A, Bertuzzi A et al.. Sorafenib is active on lung metastases from synovial sarcoma. Ann Oncol 2009; 20: 386-396.
27. Ray-Coquard I, Italiano A, Bompas E et al.. Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist 2012; 17: 260-266.
28. Sleijfer S, Ray-Coquard I, Papai Z et al.. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J Clin Oncol 2009; 27(19): 3126-3132.
29. van der Graaf WT, Blay J, Chawla SP et al.. Pallette: a randomized, double-blind phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-an EORTC STBSG Global Network Study (EORTC 62072). 2011 ASCO Annual Meeting [Abstract no. LBA10002]. J Clin Oncol 2011; 29.